Putative roles for BMSCs during infection
Phase 1: Pathogen and damage signal detection |
BMSCs |
TLR-mediated modulation of activation and function28-32,34-36,54 |
Recruitment to site of infection through chemotaxis gradients52,54,71 |
Phase 2: Activation of host immune response |
BMSC effects on HSCs |
Maintenance of quiescent HSC pool56,57 |
BM emigration of activated HSCs57 |
BMSC effects on immune effector cells |
Mobilization and emigration from BM58 |
Thymic development to augment immune effector cell response79-82 |
Phase 3: Pathogen elimination |
BMSC effects on pathogen |
Production of microbiocidal soluble factors3,60,61 |
Containment of infectious pathogen within microenvironment (eg, pathogen phagocytosis)62 |
Enhance microbiocidal function of immune effector cells62,83 |
Phase 4: Induction of pro-inflammatory gradients |
BMSC production of immunomodulatory soluble factors |
Antioxidant soluble factors (HO-1)45,46 |
Anti-inflammatory soluble factors (galectin-1, IDO, IL-10, HGF, HLA-G5, PGE2, TGFβ, TSG-6)2-4,47,52-54,67,72,84 |
Phase 5: Modulation of pro-inflammatory host immune response |
BMSC-mediated effects on host immune response and on immune-induced damage to the host |
Effects on immune effector cell activation, differentiation, function, or migration47,52-54,73,75,84 |
Augment wound healing, minimize tissue cytotoxicity, or enhance revascularization62-64,71,72 |
Modulation of inflammation and organ dysfunction after in vivo infectious challenge61-64 |
Phase 1: Pathogen and damage signal detection |
BMSCs |
TLR-mediated modulation of activation and function28-32,34-36,54 |
Recruitment to site of infection through chemotaxis gradients52,54,71 |
Phase 2: Activation of host immune response |
BMSC effects on HSCs |
Maintenance of quiescent HSC pool56,57 |
BM emigration of activated HSCs57 |
BMSC effects on immune effector cells |
Mobilization and emigration from BM58 |
Thymic development to augment immune effector cell response79-82 |
Phase 3: Pathogen elimination |
BMSC effects on pathogen |
Production of microbiocidal soluble factors3,60,61 |
Containment of infectious pathogen within microenvironment (eg, pathogen phagocytosis)62 |
Enhance microbiocidal function of immune effector cells62,83 |
Phase 4: Induction of pro-inflammatory gradients |
BMSC production of immunomodulatory soluble factors |
Antioxidant soluble factors (HO-1)45,46 |
Anti-inflammatory soluble factors (galectin-1, IDO, IL-10, HGF, HLA-G5, PGE2, TGFβ, TSG-6)2-4,47,52-54,67,72,84 |
Phase 5: Modulation of pro-inflammatory host immune response |
BMSC-mediated effects on host immune response and on immune-induced damage to the host |
Effects on immune effector cell activation, differentiation, function, or migration47,52-54,73,75,84 |
Augment wound healing, minimize tissue cytotoxicity, or enhance revascularization62-64,71,72 |
Modulation of inflammation and organ dysfunction after in vivo infectious challenge61-64 |